Drugmaker Indivior's finance chief Preblick to step down
Published by Global Banking & Finance Review®
Posted on December 17, 2024
1 min readLast updated: January 27, 2026

Published by Global Banking & Finance Review®
Posted on December 17, 2024
1 min readLast updated: January 27, 2026

Indivior's finance chief Ryan Preblick resigns amid board changes influenced by Oaktree Capital, with new directors appointed and a shift to US remuneration standards.
(Reuters) - Indivior said on Tuesday its finance chief Ryan Preblick will step down as the British drugmaker makes changes to its board following pressure from no.2 shareholder Oaktree Capital.
The maker of opioid addiction treatment Sublocade also appointed Robert Schriesheim and Joe Ciaffoni as independent non-executive directors, and said it has agreed to move towards a more standard U.S. system of remuneration for directors following its recent primary listing in New York.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sherry Jacob-Phillips)
The article discusses the resignation of Indivior's finance chief Ryan Preblick and subsequent board changes influenced by Oaktree Capital.
Robert Schriesheim and Joe Ciaffoni have been appointed as independent non-executive directors.
Indivior is moving towards a more standard US system of remuneration for directors following its New York listing.
Explore more articles in the Finance category


